About VenoStent
VenoStent is a company based in Nashville (United States) founded in 2017. VenoStent has raised $23.36 million across 11 funding rounds from investors including NIH, HHS and Norwest Venture Partners. VenoStent offers products and services including SelfWrap. VenoStent operates in a competitive market with competitors including Invizius, Renal Solutions, Redsense Medical, Doto Medical and Health Line International Corporation, among others.
- Headquarter Nashville, United States
- SectorsHealthcare
- Email••••••••
- Website venostent.com
- Social LinkedIn X
- Legal Name Venostent, Inc
- Total Equity Funding$23.36M (USD)
in 11 rounds
- InvestorsNIH
& 16 more
Products & Services of VenoStent
VenoStent offers a comprehensive portfolio of products and services, including SelfWrap.
Bioabsorbable wrap designed to prevent failures in dialysis access sites.
Funding Insights of VenoStent
VenoStent has successfully raised a total of $23.36M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $23.36M
- Total Rounds 11
- First Round $70,000
(Mar 2018)
- Investors Count 17
Latest 10 of 11 funding rounds of VenoStent with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2026 | – | Series A | – | – | – |
| Jun 2024 | $3.6M | Grant | – | – | |
| Jun 2024 | $4M | Series A | – | Good Growth Capital, IAG Capital Partners | |
| Jul 2023 | $16.06M | Series A | – | Good Growth Capital, IAG Capital Partners | |
| Feb 2021 | $2.3M | Seed | – | Creative Ventures | |
| Aug 2020 | $150,000 | Seed | – | Y Combinator | – |
| May 2020 | $515,000 | Seed | – | – | – |
| Apr 2020 | $1.51M | Grant | – | – | |
| Aug 2019 | $794,224 | Grant | – | – | |
| Jul 2019 | $263,929 | Seed | – | – | – |
17 investors in total: 17 institutional.
Investors in VenoStent
VenoStent has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Norwest Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors. | 1961 | nvp.com | Menlo Park, United States | |
Early-stage investments are made in life sciences and technologies. | 2017 | goodgrowthvc.com | Charleston, United States | |
Venture capital investments are provided by IAG Capital Partners. | – | iagcapitalpartners.com | Charleston, USA | |
Early-stage Life-Sciences & Offline focused VC firm funding companies in the US | – | tmcventurefund.com | Houston, United States | |
Venture capital investments are provided to startups by SNR Ventures. | – | snr.vc | - | |
Early-stage capital is provided by Baylor Angel Network. | – | baylorangelnetwork.com | - | |
Creative Ventures is focused on deep tech venture investments. | – | creativeventures.vc | San Francisco Bay Area, United States | |
Cowtown Angels is recognized as Fort Worth's leading angel investor network. | – | cowtownangels.org | Fort Worth, United States | |
Venture capital investing and portfolio management services for accredited investors. | – | av.vc | - | |
Investments in tech sectors are handled by Olima Ventures. | – | olimaventures.com | New York, United States |
Investor details for VenoStent
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of VenoStent
3 people are tracked at VenoStent (2 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Timothy Boire | CEO | Leadership |
Geoffrey Lucks | COO and Cofounder | Leadership |
Raul Aguilar | Senior Facilities & Operations Manager | Team |
Complete people profiles for VenoStent
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of VenoStent
3 dated milestones of VenoStent across 9 years, from founding to its latest funding, stage changes and deals.
- Founded VenoStent is founded.
- Funding First funding round of $70K.
- Funding Latest funding round, Series A,.
Competitors of VenoStent
VenoStent operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Invizius, Renal Solutions, Redsense Medical, Doto Medical and Health Line International Corporation, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| invizius.com | 2018 | Edinburgh, United Kingdom | $13.09M | 12 | Priming solutions for hemodialyzers are developed to reduce blood reactions. | |
| renalsolutionsinc.com | 2000 | Warrendale, United States | $34.5M | – | Sorbents for renal replacement therapy are developed using regenerative technology. | |
| redsensemedical.com | 2006 | Halmstad, Sweden | – | – | Blood access is monitored during hemodialysis via alarm systems. | |
| dotomedical.com | 2023 | Wrocaw, Poland | – | – | Develops medical devices to enhance hemodialysis and treat kidney disease. | |
| hlic.net | 2004 | Salt Lake, United States | – | – | Contract Manufacturer of Dialysis products, Also sells own product lines. | |
| medcomp.net | 1978 | – | – | – | - | |
| peaceandquietcare.co.uk | 2017 | Manchester, United Kingdom | – | – | Develops innovative renal dialysis machines with soundproof boxes. | |
| oasproject.com | 2016 | Madrid, Spain | – | – | Develops accessory devices to support dialysis treatments. | |
| oxyless.com | 2010 | London, United Kingdom | – | – | Develops bloodlines for dialysis treatments to enhance patient care. |
Detailed competitors of VenoStent
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Venostent
Complete news archive for VenoStent
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to VenoStent
10 companies that operate in the same segment as VenoStent (Nephrology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Implantable battery-powered pumps for ascites removal are developed. | 2006 | Zurich, Switzerland | USD 35.5 M | – | – | |
Hemodialysis machines with touchscreen displays are provided for medical use. | 2003 | San Jose, California, United States | USD 467.37 M | USD 119.48 M | – | |
Haemodialysis systems are developed for home and clinic applications. | 2008 | Alcester, Warwickshire, United Kingdom | USD 432.84 M | USD 1.4 M | 100 | |
Provider of small molecule based drug for inflammatory kidney disease | 2004 | Stockholm, Sweden | USD 44.83 M | – | 40 | |
Therapeutics are developed for diseases with impaired kidney function. | 2014 | Lyon, Auvergne-rhone-alpes, France | USD 120.34 M | – | – | |
Therapeutics for kidney disease treatment are developed by Akebia Therapeutics. | 2007 | Cincinnati, Ohio, United States | USD 91 M | USD 236.2 M | 181 | |
Biotherapeutics for life-threatening diseases are developed, produced, and commercialized. | 2006 | Pune, Maharashtra, India | – | USD 45.26 M | 705 | |
Biomarker-based diagnostic solutions for cancer and cardiovascular diseases are developed. | 2002 | Hennigsdorf, Brandenburg, Germany | USD 36.14 M | – | – | |
Therapeutics for various kidney diseases are developed. | 2018 | Shanghai, China | USD 114.5 M | – | – | |
Developer of portable hemodialysis device | 2013 | Irvine, California, United States | USD 82.5 M | – | 40 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about VenoStent
VenoStent was founded in 2017 and raised its 1st funding round 1 year after it was founded.
VenoStent is headquartered in Nashville, United States. It is registered at Nashville, Tennessee, United States.
Timothy Boire is the current CEO of VenoStent.
VenoStent is a funded company, having raised a total of $23.36M across 11 funding rounds to date. The company's 1st funding round was a Seed of $263.93K, raised on Mar 2018.
VenoStent was founded in 2017 and is based in Nashville, United States. The company operates in the medical device sector, focusing on vascular surgery solutions. A shape memory polymer stent, known as SelfWrap, is developed as an external wrap for venous access in hemodialysis patients. Mechanical support is provided to reduce vein collapse and promote vein growth at surgical sites.
VenoStent's top competitors include Invizius, Redsense Medical and Renal Solutions.
VenoStent offers SelfWrap.
VenoStent has 17 investors. Key investors include NIH, HHS, Norwest Venture Partners, Good Growth Capital, and IAG Capital Partners.
VenoStent operates through Venostent, Inc.